MX2017003269A - Detección de las proteínas mal plegadas. - Google Patents

Detección de las proteínas mal plegadas.

Info

Publication number
MX2017003269A
MX2017003269A MX2017003269A MX2017003269A MX2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A
Authority
MX
Mexico
Prior art keywords
protein
misfolded
soluble
monomeric
sample
Prior art date
Application number
MX2017003269A
Other languages
English (en)
Spanish (es)
Inventor
K Vollrath Benedikt
M Lebovitz Russell
Shahnawaz Mohammad
Soto Jara Claudio
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2017003269A publication Critical patent/MX2017003269A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
MX2017003269A 2014-09-11 2015-09-11 Detección de las proteínas mal plegadas. MX2017003269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049306P 2014-09-11 2014-09-11
PCT/US2015/049844 WO2016040907A1 (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Publications (1)

Publication Number Publication Date
MX2017003269A true MX2017003269A (es) 2017-12-04

Family

ID=55454515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003269A MX2017003269A (es) 2014-09-11 2015-09-11 Detección de las proteínas mal plegadas.

Country Status (15)

Country Link
US (1) US20160077112A1 (enExample)
EP (2) EP3191599B1 (enExample)
JP (2) JP6980953B2 (enExample)
KR (1) KR102448128B1 (enExample)
CN (1) CN107208125A (enExample)
AU (1) AU2015314783B2 (enExample)
BR (1) BR112017004899A2 (enExample)
CA (1) CA2960830C (enExample)
ES (1) ES2953855T3 (enExample)
HR (1) HRP20231232T1 (enExample)
IL (2) IL251052B (enExample)
MX (1) MX2017003269A (enExample)
PL (1) PL3191599T3 (enExample)
SG (2) SG11201701953RA (enExample)
WO (1) WO2016040907A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
GB201611840D0 (en) * 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
TW201901153A (zh) * 2017-05-16 2019-01-01 美商安培恩股份有限公司 折疊錯誤之tau蛋白的檢測及檢測折疊錯誤之tau蛋白的套組
CA3074914A1 (en) 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2019121952A1 (en) * 2017-12-21 2019-06-27 H. Lundbeck A/S Assay, method and treatment of alpha-synucleinopathies
CN108088816A (zh) * 2018-01-23 2018-05-29 深圳市国赛生物技术有限公司 小型特定蛋白分析仪
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
US20190353669A1 (en) * 2018-05-16 2019-11-21 Amprion, Inc. Detection of Brain Injury or Neurological Disease using Tau Protein
CA3110200C (en) * 2018-09-21 2023-08-08 Deepmind Technologies Limited Iterative protein structure prediction using gradients of quality scores
JP7376040B2 (ja) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 神経変性疾患におけるバイオマーカー分子の検出方法
IL291067B1 (en) * 2019-09-04 2026-05-01 Amprion Inc Detection of alpha-synuclein using beads
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
WO2021198098A1 (en) 2020-04-03 2021-10-07 Universität Zürich Improved method of detecting biomarkers in a biological sample
KR20230029638A (ko) * 2020-05-18 2023-03-03 암프리온, 인코퍼레이티드 알파-시누클레인 기질 및 이를 제조 및 사용하는 방법
CA3199642A1 (en) * 2020-11-21 2022-05-27 Shuwen Biotech Co. Ltd. Apparatus and method for detecting misfolded protein in biological sample
WO2022221876A1 (en) * 2021-04-15 2022-10-20 The Brigham And Women's Hospital, Inc. Digital protein misfolding assays
CN114199875B (zh) * 2022-02-18 2022-05-20 之江实验室 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000226A (es) 2000-07-07 2004-05-21 Applied Research Systems Diagnosticos tempranos de enfermedades conformacionales.
CA2433754A1 (en) * 2001-01-03 2002-07-11 Ortho-Mcneil Pharmaceutical, Inc. Alpha synuclein aggregation assays
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
AU2006214463B2 (en) * 2005-02-15 2012-08-30 Presympto, Inc. Method for detecting misfolded proteins and prions
CA2652770A1 (en) * 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
WO2008030973A2 (en) * 2006-09-06 2008-03-13 The Board Of Regents Of The University Of Texas System Methods and compositions for the detection of protein folding disorders
JP2010043865A (ja) * 2006-12-12 2010-02-25 Olympus Corp 異常型プリオンの検出方法
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method
US9133343B2 (en) * 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
US9910049B2 (en) * 2014-09-11 2018-03-06 Amprion, Inc. Detection of misfolded amyloid beta protein
EP2666020A1 (en) * 2011-01-18 2013-11-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for amplification and detection of prions
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof

Also Published As

Publication number Publication date
KR102448128B1 (ko) 2022-09-27
KR20170103741A (ko) 2017-09-13
AU2015314783B2 (en) 2021-10-21
JP2017530373A (ja) 2017-10-12
SG11201701953RA (en) 2017-04-27
US20160077112A1 (en) 2016-03-17
JP7104943B2 (ja) 2022-07-22
EP4292654A2 (en) 2023-12-20
EP3191599A1 (en) 2017-07-19
CN107208125A (zh) 2017-09-26
IL291809A (en) 2022-06-01
IL251052B (en) 2022-05-01
WO2016040907A1 (en) 2016-03-17
SG10202008464UA (en) 2020-10-29
CA2960830C (en) 2023-09-05
CA2960830A1 (en) 2016-03-17
JP6980953B2 (ja) 2021-12-15
EP4292654A3 (en) 2024-01-03
EP3191599A4 (en) 2018-03-14
IL291809B2 (en) 2023-06-01
JP2022000629A (ja) 2022-01-04
EP3191599B1 (en) 2023-08-02
HRP20231232T1 (hr) 2024-01-19
PL3191599T3 (pl) 2023-12-27
BR112017004899A2 (pt) 2017-12-12
AU2015314783A1 (en) 2017-04-27
EP3191599C0 (en) 2023-08-02
IL251052A0 (en) 2017-04-30
ES2953855T3 (es) 2023-11-16

Similar Documents

Publication Publication Date Title
EP4292654A3 (en) Detection of misfolded proteins
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
WO2015114506A3 (en) Biosensors for the detection of infection and associated maladies
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
MX2019007653A (es) Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana.
PH12019550236A1 (en) Detection of misfolded tau protein
MX2021007667A (es) Composiciones y metodos para detectar un contaminante biologico.
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
WO2016209773A9 (en) Improved assays and methods for allergen detection
MX2023005452A (es) Deteccion de beta amiloide por espectrometria de masas.
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
EP4067507A3 (en) Pna probes, kits and methods for detecting genotypes of human papillomavirus
PH12017500765A1 (en) Malaria detection
MX395376B (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
SG10201806729VA (en) Novel assay to detect human periostin
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
EP4407047A3 (en) Molecular detection of enterovirus and parechovirus
SG10201901836PA (en) Test strip assembly
MX2018006146A (es) Modificación de diana para seguimiento y detección.
MX2017008748A (es) Ensayo para detectar dipeptidil peptidasa iv (dpp-4) humana.
WO2015193552A3 (en) Means and methods for determining risk of type-1 diabetes by serum protein biomarkers
WO2017053703A3 (en) Composition and methods for assessing sensitivity and specificity of antibody detection reagents
WO2019013613A3 (es) Métodos y kits para determinar el riesgo de cáncer
MX2016007789A (es) Chip de arn para la deteccion precoz de diabetes tipo ii y sindrome metabolico.